Removal of ticagrelor by hemoadsorption with the HA380 cartridge.

IF 2.2 3区医学 Q3 HEMATOLOGY

Blood Purification Pub Date : 2025-02-18 DOI:10.1159/000544770

Taku Furukawa, Yugeesh R Lankadeva, Ian C Baldwin, Pei Chen Connie Ow, Sally Hood, Youssef Daali, Antoine Schneider, Laurent A Decosterd, Clive N May, Rinaldo Bellomo

{"title":"Removal of ticagrelor by hemoadsorption with the HA380 cartridge.","authors":"Taku Furukawa, Yugeesh R Lankadeva, Ian C Baldwin, Pei Chen Connie Ow, Sally Hood, Youssef Daali, Antoine Schneider, Laurent A Decosterd, Clive N May, Rinaldo Bellomo","doi":"10.1159/000544770","DOIUrl":null,"url":null,"abstract":"Introduction: Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose.Methods: Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 hours. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points.Results: The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 minutes, which declined rapidly to 2.66% (SD 18.5) at 120 minutes and 0.48% (SD 17.0) at 240 minutes. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 minutes. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 minutes to near zero at 120 and 240 minutes.Conclusion: HA with the HA380 cartridge can achieves an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-12"},"PeriodicalIF":2.2000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544770","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hemoadsorption has emerged as a potential intervention for the removal of ticagrelor. We aimed to evaluate the efficacy of the HA380 hemoadsorption cartridge for this purpose.

Methods: Six healthy adult sheep received 270 mg of ticagrelor via an orogastric tube, followed by hemoadsorption using a HA380 cartridge for a duration of 4 hours. The sorbent-based removal ratio, clearance, and mass removal rate were assessed at multiple time points.

Results: The HA380 cartridge achieved an initial sorbent-based removal ratio of 48.9% (SD 11.8) at 10 minutes, which declined rapidly to 2.66% (SD 18.5) at 120 minutes and 0.48% (SD 17.0) at 240 minutes. Clearance followed a similar trend, starting at 46.1 mL/min (SD 11.4) and decreasing to 0.08 mL/min (SD 16.8) at 240 minutes. The mass removal rate also dropped significantly over time, from 3.74 ng/min (SD 2.54) at 10 minutes to near zero at 120 and 240 minutes.

Conclusion: HA with the HA380 cartridge can achieves an early 50% adsorption level for ticagrelor. If frequently changed, the HA380 cartridge may serve as a potential option for ticagrelor removal, when clinically indicated.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Purification 医学-泌尿学与肾脏学

CiteScore

5.80

自引率

3.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.